vemurafenib and cobimetinib in patients with braf-mutated melanoma
Published 1 year ago • 214 plays • Length 4:05Download video MP4
Download video MP3
Similar videos
-
2:02
trial results of vemurafenib, cobimetinib and ldh as a predictive marker in braf-mutated melanoma
-
3:08
os rates and prognostic categories for braf-mutated melanoma when treated with combination therapy
-
2:04
combination therapies with vemurafenib in braf v600e–mutant cancers
-
3:33
cobimetinib plus vemurafenib for advanced braf-mutated melanoma
-
2:58
role of braf mutation in the treatment for melanoma
-
1:30
what to do with braf-mutant melanoma patients who have a poor prognosis?
-
2:29
braf mutated melanoma: targeted or immunotherapy?
-
2:10
combined treatment with braf and mek inhibitors in metastatic melanomas with braf mutations
-
1:48
secombit – determining the order of sequential therapies in metastatic melanoma with braf mutations
-
1:17
treatment selection for stage iii braf-mutant melanoma
-
2:10
using biomarkers to predict response to combination therapies in braf-mutant melanoma
-
6:36
imspire 150: atezolizumab, cobimetinib and vemurafenib in untreated patients with brafv600 mutat...
-
2:25
biomarker analysis of cobrim: combined vemurafenib and cobimetinib for braf-mutated melanoma
-
2:40
neoadjuvant targeted therapy in braf v600 mutated melanoma
-
6:58
triplet therapies for advanced metastatic melanoma
-
6:22
vemurafenib in patients with braf600 mutation–positive metastatic melanoma
-
20:35
hitting the mark with targeted therapy: braf, nras, ckit, etc...sullivan
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
1:25
targeting ras oncogenes in patients with nras-mutated melanoma